ijms-logo

Journal Browser

Journal Browser

The Activity and Underlying Mechanisms of Anticancer Drugs

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: 20 October 2025 | Viewed by 801

Special Issue Editor


E-Mail Website
Guest Editor
Laboratory of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, 50162 Kaunas, Lithuania
Interests: tumor microenvironment; cell migration and invasion; three-dimensional cultures; preclinical development; targeted nanotherapy

Special Issue Information

Dear Colleagues,

The fight against cancer remains one of the most challenging and critical areas of medical research. With the continuous evolution of cancer cells and the emergence of new subtypes, the development of effective anticancer drugs has become increasingly complex. This Special Issue aims to explore the latest advances in the activity and underlying mechanisms of anticancer drugs, shedding light on the intricate interplay between these agents and their targets within the cancer microenvironment.

This Special Issue welcomes original research articles and reviews. Areas of research may include (but are not limited to) the following:

  • Detailed investigation of how anticancer drugs interact with their molecular targets, leading to the inhibition of cancer cell proliferation, migration, and invasion.
  • Understanding the mechanisms of drug resistance in cancer cells and strategies to overcome these barriers to effective treatment.
  • Analysis of the latest targeted therapies, including those targeting specific genetic mutations, signalling pathways, and cell surface receptors.
  • Discuss the role of personalised medicine in selecting and optimising cancer drug regimens based on individual patient characteristics and tumour profiles.

Prof. Dr. Vilma Petrikaitė
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer drugs
  • molecular mechanisms of drug action
  • drug resistance
  • novel targeted therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 1638 KiB  
Review
L-3-[18F]-Fluoro-α-Methyl Tyrosine as a PET Tracer for Tumor Diagnosis: A Systematic Review from Mechanisms to Clinical Applications
by Mei Bao, Xiang Gu, Kai Tong, Fei Chu, Pinmao Ye, Kazuko Kaneda-Nakashima, Wenbin Hou, Yiliang Li and Ling Wei
Int. J. Mol. Sci. 2025, 26(12), 5848; https://doi.org/10.3390/ijms26125848 - 18 Jun 2025
Viewed by 510
Abstract
L-3-[18F]-fluoro-α-methyl tyrosine ([18F]FAMT) is an amino acid positron emission tomography (PET) tracer with high specificity for malignant tumors through its selective transport via L-type amino acid transporter (LAT) 1. Although extensively studied for its diagnostic performance, a comprehensive review [...] Read more.
L-3-[18F]-fluoro-α-methyl tyrosine ([18F]FAMT) is an amino acid positron emission tomography (PET) tracer with high specificity for malignant tumors through its selective transport via L-type amino acid transporter (LAT) 1. Although extensively studied for its diagnostic performance, a comprehensive review of its molecular and clinical characteristics remains lacking. A systematic literature review (1997–2025) was conducted using PubMed and Web of Science, with keywords including “L-3-[18F]-fluoro-α-methyl tyrosine”, “[18F]FAMT”, “amino acid PET”, and “tumor imaging”. The review covered aspects of synthesis, structural properties, pharmacokinetics, and clinical applications. Notably, while research on [18F]FAMT has declined significantly in recent years, [18F]FAMT PET demonstrates superior specificity to [18F]FDG PET in distinguishing malignancies from inflammatory lesions and offers distinct advantages in lung, esophageal, and oral cancers, though with slightly lower sensitivity. Its key features include tumor-specific uptake patterns, rapid blood clearance, and a significant correlation between its uptake levels and both LAT1 expression and tumor proliferation. In conclusion, [18F]FAMT is a promising PET tracer with notable advantages in tumor imaging, particularly due to its LAT1 selectivity and favorable pharmacokinetics. Despite challenges in production, these characteristics underscore its clinical value in cancers requiring precise imaging. Future research should focus on optimizing synthesis, expanding clinical validation, and exploring theranostic applications. Full article
(This article belongs to the Special Issue The Activity and Underlying Mechanisms of Anticancer Drugs)
Show Figures

Figure 1

Back to TopTop